The MYB gene as a model for global transcriptional regulation: stopping, starting and looping. This project will study how transcriptional elongation controls the MYB gene, a key regulator of normal and cancerous growth and regulation. There are three major benefits that are likely to flow from the proposed research It will strengthen research in new and important areas of transcriptional regulation, by building research capacity in Australia in the area of gene expression, particularly with res ....The MYB gene as a model for global transcriptional regulation: stopping, starting and looping. This project will study how transcriptional elongation controls the MYB gene, a key regulator of normal and cancerous growth and regulation. There are three major benefits that are likely to flow from the proposed research It will strengthen research in new and important areas of transcriptional regulation, by building research capacity in Australia in the area of gene expression, particularly with respect to transcriptional elongation and long-range regulation. It will highlight a new approach to the therapeutic targeting of MYB in cancer: data generated from this research may enable us to target MYB expression in a range of cancers including breast cancer by inhibiting transcriptional elongation. And it will provide training in advanced molecular biology to postdoctoral scientists and students.Read moreRead less
Targeted development of dual action antitumour and antiangiogenic agents using differential and functional proteomics. There is an enormous need to develop more effective and less toxic therapeutic approaches to reduce the social and economic burden of cancer. The recent identification of small molecules that can act by both destroying cancer cells and the blood vessels that carry nutrients to them has provided a unique opportunity to define the pathways involved in the action of these agents in ....Targeted development of dual action antitumour and antiangiogenic agents using differential and functional proteomics. There is an enormous need to develop more effective and less toxic therapeutic approaches to reduce the social and economic burden of cancer. The recent identification of small molecules that can act by both destroying cancer cells and the blood vessels that carry nutrients to them has provided a unique opportunity to define the pathways involved in the action of these agents in order to develop more potent drug analogues. Development of these molecules will involve a collaborative and multidisciplinary link with our industry partner and the use of frontier technologies that may lead to improved health and economic outcomes for Australia. Read moreRead less
How IGFBP-3 improves cancer cell responsiveness to DNA-damaging therapies. A protein called IGFBP-3 can modulate the way cancer cells respond to treatments such as radiotherapy and certain chemotherapy drugs. These therapies, which act by damaging cells' DNA, play an important role in the treatment of many cancers, but their effectiveness is limited by the ability of cells to oppose the treatment by repairing damaged DNA. This project aims to discover how IGFBP-3 acts to change cancer cells' res ....How IGFBP-3 improves cancer cell responsiveness to DNA-damaging therapies. A protein called IGFBP-3 can modulate the way cancer cells respond to treatments such as radiotherapy and certain chemotherapy drugs. These therapies, which act by damaging cells' DNA, play an important role in the treatment of many cancers, but their effectiveness is limited by the ability of cells to oppose the treatment by repairing damaged DNA. This project aims to discover how IGFBP-3 acts to change cancer cells' response to treatment, using breast cancer cells growing in culture as a model system. This work has the potential to lead to improvements in the treatment of cancer patients by increasing our understanding of what happens when cancer cells are exposed to radio- or chemotherapy.Read moreRead less